UBS O'Connor’s Genocea Biosciences, Inc. GNCA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-19,170
Closed -$45K 1078
2021
Q2
$45K Hold
19,170
﹤0.01% 862
2021
Q1
$52K Hold
19,170
﹤0.01% 793
2020
Q4
$46K Hold
19,170
﹤0.01% 569
2020
Q3
$44K Hold
19,170
﹤0.01% 305
2020
Q2
$44K Sell
19,170
-290
-1% -$668 ﹤0.01% 380
2020
Q1
$33K Hold
19,460
﹤0.01% 335
2019
Q4
$40K Hold
19,460
﹤0.01% 302
2019
Q3
$56K Hold
19,460
﹤0.01% 294
2019
Q2
$76K Buy
+19,460
New +$102K ﹤0.01% 228
2015
Q4
Sell
-2,500
Closed -$137K 586
2015
Q3
$137K Buy
+2,500
New +$248K ﹤0.01% 458

Other funds holding GNCA

UBS O'Connor's GNCA Position: Q3 2021 in Review

UBS O'Connor sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2021, closing a stake of 19,170 shares — an estimated $45K sold.

UBS O'Connor first reported a position in GNCA in Q3 2015 and held it in 10 quarters. The position peaked at $137K in Q3 2015. 40 funds tracked by Wall St. Rank hold GNCA as of Q3 2021.

  • UBS O'Connor reported no remaining Genocea Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • UBS O'Connor sold 19,170 Genocea Biosciences, Inc. shares in Q3 2021, an estimated $45K.
  • UBS O'Connor first reported a position in Genocea Biosciences, Inc. in Q3 2015 and held it in 10 quarters.
  • UBS O'Connor's Genocea Biosciences, Inc. position peaked at $137K in Q3 2015.
  • 40 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2021.

Based on UBS O'Connor's 13F filing for Q3 2021, filed 12 Nov 2021.